Jeff Brown’s Top 5 Biotech IPOs of 2021
“Timed Stocks” are what Silicon Valley legend Jeff Brown calls stocks that, thanks to the federal government, have a preset countdown “timer” attached to their share price…

And the exact second the timer hits zero, the stock can skyrocket (up to a rare 23,200% in a day).
It’s $199 worth of research… but you can get it for FREE.

FPRX Insider Trading (Five Prime Therapeutics)

Insider Ownership Percentage: 6.40%
Insider Buying (Last 12 Months): $5,126,065.50
Insider Selling (Last 12 Months): $149,271,534.60

Five Prime Therapeutics Insider Trading History Chart

Five Prime Therapeutics Share Price & Price History

▲ +0.01 (0.03%)
As of 03/8/2021 04:59 PM ET
Days: 30 | 90 | 365
Jeff Brown’s Top 5 Biotech IPOs of 2021
Jeff Brown just released a new research report.

It’s called The Top 5 Biotech IPOs of 2021.
It’s $199 worth of research… but you can get it for FREE.

Five Prime Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/11/2020Bvf Partners L P/IlInsiderSell7,393,340$20.19$149,271,534.60  
11/6/2020Bvf Partners L P/IlMajor ShareholderBuy30,000$4.98$149,400.00  
11/4/2020Bvf Partners L P/IlMajor ShareholderBuy416,562$4.88$2,032,822.56  
10/6/2020Bvf Partners L P/IlMajor ShareholderBuy345,241$5.04$1,740,014.64  
9/22/2020Bvf Partners L P/IlMajor ShareholderBuy32$3.80$121.60  
5/14/2020Bvf Partners L P/IlMajor ShareholderBuy293,587$4.10$1,203,706.70  
12/9/2019Bvf Partners L P/IlMajor ShareholderBuy135,000$4.02$542,700.00  
12/2/2019Franklin M BergerDirectorSell32,090$3.92$125,792.8052,890  
11/22/2019Bvf Partners L P/IlMajor ShareholderBuy1,120,010$3.40$3,808,034.00  
11/21/2019Andrew T FeldsteinCIOBuy25,560$49.37$1,261,897.20
11/5/2019Bvf Partners L P/IlMajor ShareholderBuy968,112$4.00$3,872,448.00  
10/31/2019Bvf Partners L P/IlMajor ShareholderBuy6,833$3.85$26,307.05  
10/31/2019Value Fund L P BiotechnologyInsiderBuy29,314$4.20$123,118.80
10/29/2019Bvf Partners L P/IlMajor ShareholderBuy2,400$3.90$9,360.00  
10/25/2019Bvf Partners L P/IlMajor ShareholderBuy30,782$3.75$115,432.50  
10/25/2019Value Fund L P BiotechnologyInsiderBuy169,370$4.10$694,417.00
10/23/2019Bvf Partners L P/IlMajor ShareholderBuy3,200$3.75$12,000.00  
10/8/2019Value Fund L P BiotechnologyInsiderBuy601,482$3.74$2,249,542.68
10/7/2019Bvf Partners L P/IlMajor ShareholderBuy525,070$3.75$1,969,012.50  
10/4/2019Bvf Partners L P/IlMajor ShareholderBuy16,000$3.74$59,840.00  
See Full Table

SEC Filings (Institutional Ownership Changes) for Five Prime Therapeutics (NASDAQ:FPRX)

67.28% of Five Prime Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Five Prime Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
3/8/2021Teachers Retirement System of The State of Kentucky33,118$0.56M0.0%N/A0.087%
3/8/2021Dimensional Fund Advisors LP1,543,780$26.26M0.0%-2.5%4.059%
3/4/2021Hudson Bay Capital Management LP450,000$7.66M0.1%+1,185.7%1.183%
2/25/2021Dimensional Fund Advisors LP1,543,780$26.26M0.0%-2.5%4.059%
2/24/2021Alyeska Investment Group L.P.209,691$3.57M0.1%N/A0.551%
2/19/2021JPMorgan Chase & Co.168,735$2.87M0.0%-16.8%0.444%
2/18/2021Ghost Tree Capital LLC500,000$8.51M1.8%N/A1.314%
2/16/2021Walleye Capital LLC80,047$1.36M0.1%N/A0.210%
2/16/2021Alyeska Investment Group L.P.209,691$3.57M0.1%N/A0.551%
2/16/2021Baker BROS. Advisors LP668,000$11.36M0.0%N/A1.756%
2/16/2021Nuveen Asset Management LLC412,982$2.21M0.0%+152.1%1.086%
2/16/2021Price T Rowe Associates Inc. MD1,697,659$28.88M0.0%N/A4.463%
2/16/2021Avidity Partners Management LP300,000$5.10M0.2%N/A0.789%
2/16/2021Charles Schwab Investment Management Inc.315,475$5.37M0.0%+11.2%0.829%
2/13/2021American International Group Inc.18,197$0.31M0.0%+13.6%0.048%
2/12/2021Opaleye Management Inc.381,900$6.50M0.8%N/A1.004%
2/12/2021The Manufacturers Life Insurance Company 18,855$0.32M0.0%N/A0.050%
2/12/2021Credit Suisse AG20,966$0.36M0.0%N/A0.055%
2/12/2021Virtus ETF Advisers LLC16,810$0.29M0.1%N/A0.044%
2/11/2021Trexquant Investment LP24,360$0.41M0.0%N/A0.064%
2/11/2021Northern Trust Corp387,256$6.59M0.0%+10.0%1.018%
2/11/2021Public Employees Retirement Association of Colorado3,958$67K0.0%-43.5%0.010%
2/11/2021First Mercantile Trust Co.1,987$34K0.0%N/A0.005%
2/11/2021Barclays PLC11,538$0.20M0.0%-94.4%0.030%
2/11/2021Citigroup Inc.7,448$0.13M0.0%+449.7%0.020%
2/10/2021Rhumbline Advisers54,312$0.92M0.0%+22.2%0.143%
2/10/2021Renaissance Technologies LLC1,334,848$22.71M0.0%-21.3%3.509%
2/10/2021QS Investors LLC66,700$1.14M0.0%+42.5%0.175%
2/10/2021Panagora Asset Management Inc.5,474$93K0.0%-97.2%0.014%
2/9/2021Wells Fargo & Company MN474,854$8.08M0.0%+178.8%1.248%
2/9/2021Bank of New York Mellon Corp173,996$2.96M0.0%+43.1%0.457%
2/9/2021Quantitative Systematic Strategies LLC19,113$0.33M0.0%N/A0.050%
2/9/2021Campbell & CO Investment Adviser LLC21,200$0.36M0.2%N/A0.056%
2/9/2021ProShare Advisors LLC14,113$0.24M0.0%N/A0.037%
2/8/2021Alliancebernstein L.P.65,800$1.12M0.0%-12.4%0.173%
2/8/2021New York State Common Retirement Fund29,500$0.50M0.0%+130.5%0.078%
2/6/2021Jennison Associates LLC32,438$0.55M0.0%N/A0.085%
2/5/2021BlackRock Inc.2,959,031$50.33M0.0%+39.6%7.779%
2/5/2021SG Americas Securities LLC9,369$0.16M0.0%N/A0.025%
2/4/2021State of Wisconsin Investment Board17,500$0.30M0.0%N/A0.046%
2/1/2021Victory Capital Management Inc.842,431$14.33M0.0%N/A2.215%
2/1/2021Assenagon Asset Management S.A.227,225$3.87M0.0%-56.9%0.597%
2/1/2021Franklin Street Advisors Inc. NC30,000$0.51M0.0%-40.0%0.079%
1/25/2021Strs Ohio4,800$81K0.0%N/A0.013%
1/19/2021Rhenman & Partners Asset Management AB250,000$4.25M0.3%N/A0.657%
11/17/2020Jane Street Group LLC21,814$0.10M0.0%-17.6%0.057%
11/16/2020AQR Capital Management LLC221,377$1.04M0.0%-36.9%0.582%
11/16/2020Squarepoint Ops LLC77,624$0.37M0.0%+305.1%0.204%
11/16/2020Boothbay Fund Management LLC14,586$69K0.0%-23.3%0.038%
11/13/2020Morgan Stanley14,689$69K0.0%-35.4%0.039%
11/13/2020Charles Schwab Investment Management Inc.283,759$1.33M0.0%+32.8%0.746%
11/12/2020JPMorgan Chase & Co.202,702$0.93M0.0%+7.6%0.533%
11/10/2020State Street Corp716,824$3.37M0.0%+6.7%1.884%
11/9/2020Acadian Asset Management LLC640,560$3.01M0.0%+20.5%1.684%
11/6/2020BlackRock Inc.2,119,146$9.96M0.0%-2.8%5.786%
11/6/2020GSA Capital Partners LLP56,422$0.27M0.0%N/A0.154%
11/5/2020California Public Employees Retirement System54,100$0.25M0.0%+49.9%0.148%
11/5/2020Wells Fargo & Company MN170,297$0.80M0.0%+277.7%0.465%
10/30/2020BNP Paribas Arbitrage SA6,443$30K0.0%+604.9%0.018%
10/15/2020Diversified Trust Co11,381$53K0.0%N/A0.031%
10/7/2020Assenagon Asset Management S.A.527,631$2.48M0.0%-18.8%1.441%
9/15/2020Two Sigma Advisers LP407,500$2.49M0.0%-2.1%1.113%
8/31/2020Bridgeway Capital Management Inc.166,500$1.02M0.0%+37.0%0.455%
8/25/2020Nuveen Asset Management LLC133,437$0.81M0.0%-16.0%0.364%
8/17/2020AQR Capital Management LLC350,930$2.14M0.0%-13.8%0.958%
8/17/2020Jacobs Levy Equity Management Inc.216,991$1.32M0.0%+1,800.9%0.592%
8/17/2020Jane Street Group LLC26,468$0.16M0.0%N/A0.072%
8/17/2020Public Employees Retirement System of Ohio19,344$0.12M0.0%N/A0.053%
8/14/2020Man Group plc216,444$1.32M0.0%-7.2%0.591%
8/14/2020PDT Partners LLC38,750$0.24M0.0%-43.9%0.106%
8/14/2020Bank of America Corp DE20,963$0.13M0.0%+18.5%0.057%
8/14/2020BVF Inc. IL7,988,053$48.73M3.0%+2.6%21.809%
8/14/2020Tudor Investment Corp Et Al24,355$0.15M0.0%-60.2%0.066%
8/13/2020First Republic Investment Management Inc.275,000$1.68M0.0%+537.1%0.751%
8/13/2020Athanor Capital LP33,943$0.21M0.0%N/A0.093%
8/12/2020American International Group Inc.16,380$100K0.0%-18.9%0.045%
8/12/2020Algert Global LLC30,445$0.19M0.1%-18.2%0.083%
8/12/2020Goldman Sachs Group Inc.165,213$1.01M0.0%+234.1%0.451%
8/12/2020Bank of New York Mellon Corp123,526$0.75M0.0%-11.9%0.337%
8/12/2020Hudson Bay Capital Management LP35,000$0.21M0.0%-75.0%0.096%
8/12/2020State of Wisconsin Investment Board17,900$0.11M0.0%N/A0.049%
8/7/2020Virtu Financial LLC14,924$91K0.0%N/A0.041%
8/7/2020New York State Common Retirement Fund12,800$78K0.0%-54.4%0.035%
8/6/2020Platinum Investment Management Ltd.327,414$2M0.0%+30.3%0.894%
8/5/2020Russell Investments Group Ltd.5,989$36K0.0%N/A0.016%
7/31/2020UBS Group AG58,547$0.36M0.0%+178.6%0.160%
7/21/2020Assenagon Asset Management S.A.650,000$3.97M0.0%+220.0%1.775%
7/20/2020SG Americas Securities LLC106,939$0.65M0.0%+76.5%0.292%
6/19/2020State Street Corp615,025$1.40M0.0%-1.8%1.679%
5/15/2020AQR Capital Management LLC407,242$0.92M0.0%-9.4%1.112%
5/15/2020Squarepoint Ops LLC28,576$65K0.0%+21.6%0.078%
5/15/2020Invesco Ltd.63,413$0.14M0.0%+122.8%0.173%
5/15/2020Tudor Investment Corp Et Al61,149$0.14M0.0%-32.5%0.167%
5/15/2020Morgan Stanley60,174$0.14M0.0%+16.2%0.164%
5/15/2020Two Sigma Investments LP388,378$0.88M0.0%-18.0%1.060%
5/15/2020Two Sigma Advisers LP416,400$0.95M0.0%+14.6%1.137%
5/14/2020Wells Fargo & Company MN33,257$76K0.0%+16.4%0.091%
5/14/2020Geode Capital Management LLC538,789$1.22M0.0%+4.5%1.471%
5/14/2020Wellington Management Group LLP1,241,020$2.82M0.0%-0.9%3.388%
5/14/2020Alliancebernstein L.P.63,600$0.14M0.0%+6.2%0.174%
Data available starting January 2016

See Full Table
Five Prime Therapeutics logo
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $37.77

50 Day Range

MA: $19.29

52 Week Range

Now: $37.77


506,230 shs

Average Volume

1,968,187 shs

Market Capitalization

$1.44 billion

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Five Prime Therapeutics?

Five Prime Therapeutics' top insider shareholders include:
  1. Franklin M Berger (Director)
  2. Andrew T Feldstein (CIO)
  3. Bvf Partners L P/Il (Insider)
  4. Bvf Partners L P/Il (Major Shareholder)
  5. Value Fund L P Biotechnology (Insider)

Who are the major institutional investors of Five Prime Therapeutics?

Five Prime Therapeutics' top institutional shareholders include:
  1. BlackRock Inc. — 7.78%
  2. Price T Rowe Associates Inc. MD — 4.46%
  3. Dimensional Fund Advisors LP — 4.06%
  4. Dimensional Fund Advisors LP — 4.06%
  5. Renaissance Technologies LLC — 3.51%
  6. Victory Capital Management Inc. — 2.21%

Which institutional investors are selling Five Prime Therapeutics stock?

Within the last quarter, FPRX stock was sold by these institutional investors:
  1. Renaissance Technologies LLC
  2. Assenagon Asset Management S.A.
  3. Barclays PLC
  4. Panagora Asset Management Inc.
  5. Dimensional Fund Advisors LP
  6. Dimensional Fund Advisors LP
  7. JPMorgan Chase & Co.
  8. Franklin Street Advisors Inc. NC

Which institutional investors are buying Five Prime Therapeutics stock?

Within the last quarter, FPRX stock was purchased by institutional investors including:
  1. Price T Rowe Associates Inc. MD
  2. Victory Capital Management Inc.
  3. BlackRock Inc.
  4. Baker BROS. Advisors LP
  5. Ghost Tree Capital LLC
  6. Hudson Bay Capital Management LP
  7. Opaleye Management Inc.
  8. Wells Fargo & Company MN
In the last year, these company insiders have bought Five Prime Therapeutics stock:
  1. Franklin M Berger (Director)
  2. Andrew T Feldstein (CIO)
  3. Bvf Partners L P/Il (Insider)
New IPO targeted by the billionaire behind Google and Amazon
The IPO stock is commercializing a NASA technology originally developed for Mars exploration. It's now made deals with 25 of the Fortune 100 companies. It trades for less than $10. And I believe it will become the most successful stock of the next decade.
Click here to learn more.